Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma

NCT03034135 is registered in ClinicalTrials.gov with Cantex Pharmaceuticals as lead sponsor.

NCT NCT03034135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03034135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma
Lead sponsor
Cantex Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
March 9, 2017
Completion date
July 10, 2018
Enrollment
23 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma